Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ)

MLA

Ernesto Wasserman, et al. “Phase I/II Study of Single Agent MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting the HER3 Pathway: Overall Safety at the Recommended Phase II Dose (R2PD) and Preliminary Activity in HER2+ Metastatic Gastric/Gastroesophageal Junction Cancer (GC/GEJ).” Annals of Oncology, vol. 29, Oct. 2018, pp. viii223-viii224. EBSCOhost, https://doi.org/10.1093/annonc/mdy282.048.

APA

Ernesto Wasserman, Petronella O. Witteveen, J.H.M. Schellens, M. Magin Ferrer, Valentina Boni, Andreea Varga, K. Bol, A. Amatu, Maria Alsina, Virtudes Moreno, & A. Lourbakos. (2018). Phase I/II study of single agent MCLA-128, a full length IgG1 bispecific antibody targeting the HER3 pathway: Overall safety at the recommended phase II dose (R2PD) and preliminary activity in HER2+ metastatic gastric/gastroesophageal junction cancer (GC/GEJ). Annals of Oncology, 29, viii223-viii224. https://doi.org/10.1093/annonc/mdy282.048

Chicago

Ernesto Wasserman, Petronella O. Witteveen, J.H.M. Schellens, M. Magin Ferrer, Valentina Boni, Andreea Varga, K. Bol, et al. 2018. “Phase I/II Study of Single Agent MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting the HER3 Pathway: Overall Safety at the Recommended Phase II Dose (R2PD) and Preliminary Activity in HER2+ Metastatic Gastric/Gastroesophageal Junction Cancer (GC/GEJ).” Annals of Oncology 29 (October): viii223-viii224. doi:10.1093/annonc/mdy282.048.